These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27914820)

  • 1. Cell therapy in critical limb ischemia: A comprehensive analysis of two cell therapy products.
    Tournois C; Pignon B; Sevestre MA; Al-Rifai R; Creuza V; Poitevin G; François C; Nguyen P
    Cytotherapy; 2017 Feb; 19(2):299-310. PubMed ID: 27914820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical limb ischemia: thrombogenic evaluation of two autologous cell therapy products and biologic profile in treated patients.
    Tournois C; Pignon B; Sevestre MA; Djerada Z; Capiod JC; Poitevin G; Delloup AM; Nguyen P
    Transfusion; 2015 Nov; 55(11):2692-701. PubMed ID: 26222701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Autologous Cell-based Therapy in Patients with No-option Critical Limb Ischaemia: A Meta-Analysis.
    Wahid FSA; Ismail NA; Wan Jamaludin WF; Muhamad NA; Mohamad Idris MA; Lai NM
    Curr Stem Cell Res Ther; 2018; 13(4):265-283. PubMed ID: 29532760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of responders to autologous bone marrow cell therapy for no-option critical limb ischemia.
    Madaric J; Klepanec A; Valachovicova M; Mistrik M; Bucova M; Olejarova I; Necpal R; Madaricova T; Paulis L; Vulev I
    Stem Cell Res Ther; 2016 Aug; 7(1):116. PubMed ID: 27530339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concise Review: Cell Therapy for Critical Limb Ischemia: An Integrated Review of Preclinical and Clinical Studies.
    Qadura M; Terenzi DC; Verma S; Al-Omran M; Hess DA
    Stem Cells; 2018 Feb; 36(2):161-171. PubMed ID: 29226477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic, Mesenchymal, and Immune Cells Are More Enhanced in Bone Marrow than in Peripheral Blood from Granulocyte Colony-Stimulating Factor Primed Healthy Donors.
    De Felice L; Agostini F; Suriano C; Fraboni D; Gregorj C; Tirindelli MC; Picardi A; Santarone S; Di Piazza F; Di Bartolomeo P; Arcese W
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1758-1764. PubMed ID: 27349920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of mouse bone marrow and adipose tissue mesenchymal stem cells for critical limb ischemia cell therapy.
    Nammian P; Asadi-Yousefabad SL; Daneshi S; Sheikhha MH; Tabei SMB; Razban V
    Stem Cell Res Ther; 2021 Jan; 12(1):58. PubMed ID: 33436054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of treatments of peripheral arterial disease with mesenchymal stromal cells and mesenchymal stromal cells modified with granulocyte and macrophage colony-stimulating factor.
    da Cunha FF; Martins L; Martin PK; Stilhano RS; Paredes Gamero EJ; Han SW
    Cytotherapy; 2013 Jul; 15(7):820-9. PubMed ID: 23660332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood CD34 Positive Cell Transplantation for Hemodialysis Patients with Critical Limb Ischemia: A Prospective Phase II Clinical Trial.
    Ohtake T; Mochida Y; Ishioka K; Oka M; Maesato K; Moriya H; Hidaka S; Higashide S; Ioji T; Fujita Y; Kawamoto A; Fukushima M; Kobayashi S
    Stem Cells Transl Med; 2018 Nov; 7(11):774-782. PubMed ID: 30059194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization and comparison of bone marrow and peripheral blood mononuclear cells used for cellular therapy in critical leg ischaemia: towards a new cellular product.
    Capiod JC; Tournois C; Vitry F; Sevestre MA; Daliphard S; Reix T; Nguyen P; Lefrère JJ; Pignon B
    Vox Sang; 2009 Apr; 96(3):256-65. PubMed ID: 19207166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative expression of adhesion molecules on granulocyte colony-stimulating factor-mobilized peripheral blood, bone marrow, and cord blood CD34+ cells.
    Gigant C; Latger-Cannard V; Bensoussan D; Feugier P; Bordigoni P; Stoltz JF
    J Hematother Stem Cell Res; 2001 Dec; 10(6):807-14. PubMed ID: 11798507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early endothelial progenitor cells in bone marrow are a biomarker of cell therapy success in patients with critical limb ischemia.
    Smadja DM; Duong-van-Huyen JP; Dal Cortivo L; Blanchard A; Bruneval P; Emmerich J; Gaussem P
    Cytotherapy; 2012 Feb; 14(2):232-9. PubMed ID: 22040109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between cell number and clinical outcomes of autologous bone-marrow mononuclear cell implantation in critical limb ischemia.
    Yusoff FM; Kajikawa M; Takaeko Y; Kishimoto S; Hashimoto H; Maruhashi T; Nakashima A; Wahid SFSA; Higashi Y
    Sci Rep; 2020 Nov; 10(1):19891. PubMed ID: 33199760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Efficacy of Autologous Non-Mobilized Enriched Circulating Endothelial Progenitors in Patients With Critical Limb Ischemia　- The SCELTA Trial.
    Liotta F; Annunziato F; Castellani S; Boddi M; Alterini B; Castellini G; Mazzanti B; Cosmi L; Acquafresca M; Bartalesi F; Dilaghi B; Dorigo W; Graziani G; Bartolozzi B; Bellandi G; Carli G; Bartoloni A; Fargion A; Fassio F; Fontanari P; Landini G; Lucente EAM; Michelagnoli S; Orsi Battaglini C; Panigada G; Pigozzi C; Querci V; Santarlasci V; Parronchi P; Troisi N; Baggiore C; Romagnani P; Mannucci E; Saccardi R; Pratesi C; Gensini G; Romagnani S; Maggi E
    Circ J; 2018 May; 82(6):1688-1698. PubMed ID: 29576595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in asymmetric dimethylarginine and oxidative stress in patients with limb salvage after autologous mononuclear stem cell application for critical limb ischemia.
    Madaric J; Valachovicova M; Paulis L; Pribojova J; Mateova R; Sebekova K; Postulkova L; Madaricova T; Bucova M; Mistrik M; Vulev I
    Stem Cell Res Ther; 2017 Jul; 8(1):165. PubMed ID: 28697789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of age, disease state, and granulocyte colony-stimulating factor on progenitor cell count and function in patients undergoing cell therapy for cardiac disease.
    Mozid AM; Jones D; Arnous S; Saunders N; Wragg A; Martin J; Agrawal S; Mathur A
    Stem Cells Dev; 2013 Jan; 22(2):216-23. PubMed ID: 22834565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo efficacy of endothelial growth medium stimulated mesenchymal stem cells derived from patients with critical limb ischemia.
    Al-Rifai R; Nguyen P; Bouland N; Terryn C; Kanagaratnam L; Poitevin G; François C; Boisson-Vidal C; Sevestre MA; Tournois C
    J Transl Med; 2019 Aug; 17(1):261. PubMed ID: 31399109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes.
    Huang P; Li S; Han M; Xiao Z; Yang R; Han ZC
    Diabetes Care; 2005 Sep; 28(9):2155-60. PubMed ID: 16123483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spontaneous and granulocyte–colony-stimulating factor-enhanced marrow response and progenitor cell mobilization in mice after myocardial infarction.
    Delgaudine M; Gothot A; Beguin Y
    Cytotherapy; 2010 Nov; 12(7):909-18. PubMed ID: 20230223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the phenotype and clonogenicity of normal CD34+ cells from umbilical cord blood, granulocyte colony-stimulating factor-mobilized peripheral blood, and adult human bone marrow.
    Steen R; Tjønnfjord GE; Egeland T
    J Hematother; 1994; 3(4):253-62. PubMed ID: 7537606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.